In the Kaplan-Meier plot, despite no significant differences in VTEs between prostate cancer patients who received different treatments, a statistically non-significant increase of VTE incidence in patients who received GnRH therapies indicated a potentially higher risk than in those who did not receive GnRH (Figure 2). The gene discussed is GNRH1; the disease is prostate carcinoma.